Actionable news
0
All posts from Actionable news
Actionable news in INO: Inovio Pharmaceuticals, Inc.,

Inovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene & Cell Therapy

PLYMOUTH MEETING, Pa., May 04, 2016 (GLOBE NEWSWIRE via COMTEX) --

Inovio Pharmaceuticals, Inc. INO, -4.78% announced today it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentations at the 19 [th] Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held in Washington, DC from May 4-7.

The ASGCT abstract review committee selected Inovio's presentation of its successful preclinical Ebola vaccine development for one of only three presentations to be given at its prestigious Presidential Symposium. In the selected abstract, out of 768 submitted and accepted, the presented preclinical testing in mice and non-human primates showed Inovio's Ebola vaccine protected 100% of immunized animals from sickness and death following exposure to a lethal dose of Ebola virus. Those results led to a study of 75 healthy subjects which showed the vaccine was safe, tolerable, and generated strong T cell and antibody responses in human as well.

Inovio's Ebola results will be offered on Friday, May 6, at 2:50 p.m. in a presentation entitled: "479 - An Optimized DNA Vaccine Formulation Protects Against Lethal Ebola Makona Virus Challenge in Non-Human Primates and Elicits Robust Immune Responses."

Dr. J. Joseph Kim, President and CEO, said, "The results we will present at the ASGCT global scientific forum demonstrate the potential and breadth of the three pillars of Inovio's broad pipeline: Immunotherapies and vaccines against cancers and challenging infectious diseases and our DNA-encoded monoclonal antibodies (dMAbs), which we believe will offer clear advantages over conventional monoclonal antibody technologies including faster development, easier product manufacturing, and more favorable pharmacokinetics."

Inovio and its collaborators will present clinical and preclinical data that supports its on-going trials exploring the next generation of immunotherapies, vaccine and monoclonal antibodies at the following times over the next two days (link to abstracts):

19th Annual Meeting of the American Society of Gene & Cell Therapy

May 5

264 - In Vivo DNA-Monoclonal Antibody (DMAb) Gene Delivery Protects Against Lethal Bacterial and Viral Challenges in Mice
5:30 - 5:45 p.m.

428 - Generation of DNA Plasmid-Encoded Neutralizing Monoclonal Antibodies In Vivo
6:00 - 8:00 p.m.

433 - DNA Monoclonal Antibodies Target Influenza Virus In Vivo
6:00 - 8:00 p.m.

435 - Skin Delivery of a RSV Vaccine with Surface Electroporation Provides...


More